On February 10, 2020, the White House released the
Administration’s budget proposal for Fiscal Year (FY) 2021, A
Budget For America’s Future. This document summarizes the President’s
recommendations
On October 9, 2019, the White House issued two executive orders with potential implications on HRSA’s ability to enforce its sub-regulatory guidance, including its patient
In a significant reversal of course, on Thursday, July 11, the White House announced that it was withdrawing a proposed rule by the Department of
The Trump administration’s fiscal year (FY) 2020 budget request, released on Monday, February 11, includes potentially harmful changes to the 340B program, increased funding for
The White House Office of Management and Budget (OMB) recently raised the thresholds for two categories of procurements – micro-purchases and small purchases – that
On February 9, 2018 the White House Council of Economic Advisors issued a White Paper on “Reforming Biopharmaceutical Pricing at Home and Abroad.” The White
President Trump’s 2019 budget request, released on February 12, 2018, included several provisions related to the 340B program. The proposed budget requires all 340B covered
The White House Office of Management and Budget (OMB) has posted an abstract of HRSA’s new proposed rule on 340B Ceiling Price and Manufacturer Civil
Last week, President Trump declared the opioid epidemic a national public health emergency. The declaration allows federal agencies “to use every appropriate emergency authority to
HRSA sent a new proposed rule on 340B Ceiling Price and Manufacturer Civil Monetary Penalties (CMPs) to the White House Office of Management and Budget
